Fintel reports that on February 3, 2025, HC Wainwright & Co. initiated coverage of CRISPR Therapeutics (NasdaqGM:CRSP) with a ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

United Therapeutics said the FDA has cleared it to begin the first clinical trial testing whether organs from gene-edited ...

KBC Group NV lifted its position in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 2,047.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and ...

Cathie Wood-led Ark Invest made significant trades involving CRSP, TXG, RBLX, ACHR, NU, ADYEY, ACCD, and AVAV.

Cathie Wood's ARK ETFs published their daily trades for Friday, January 31st, 2025, with a notable emphasis on the biotech sector. Leading the charge in purchases was CRISPR Therapeutics AG ...

The gene-editing treatment will be available to certain patients with sickle cell disease in England as Vertex commits to collecting additional data.

PFG Investments LLC lifted its stake in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 9.9% in the 4th quarter, ...

One of the world’s most expensive medicines will be used to treat some patients with sickle cell disease in England using the ...

We recently published a list of 9 Stocks Jim Cramer Talked About. In this article, we are going to take a look at where ...

CARGO Therapeutics, Inc. (CRGX – Research Report) received a Hold rating and price target from Chardan Capital analyst Geulah Livshits ...

Learn more about whether Natera, Inc. or Vertex Pharmaceuticals Incorporated is a better investment based on AAII's A+ ...